2019-23205. Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Postmarket Surveillance of Medical Devices  

  • Start Preamble


    Food and Drug Administration, HHS.




    The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.


    Fax written comments on the collection of information by November 25, 2019.


    To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, Fax: 202-395-7285, or emailed to oira_submission@omb.eop.gov. All comments should be identified with the OMB control number 0910-0449. Also include the FDA docket number found in brackets in the heading of this document.

    Start Further Info Start Printed Page 57030


    Amber Sanford, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-8867, PRAStaff@fda.hhs.gov.

    End Further Info End Preamble Start Supplemental Information


    In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

    Postmarket Surveillance of Medical Devices—21 CFR part 822

    OMB Control Number 0910-0449—Extension

    Section 522 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360 l) authorizes FDA to require a manufacturer to conduct postmarket surveillance (PS) of any device that meets the criteria set forth in the statute. The PS regulation establishes procedures that FDA uses to approve and disapprove PS plans. The regulation provides instructions to manufacturers, so they know what information is required in a PS plan submission. FDA reviews PS plan submissions in accordance with §§ 822.15 through 822.19 of the regulation, which describe the grounds for approving or disapproving a PS plan. In addition, the PS regulation provides instructions to manufacturers to submit interim and final reports in accordance with § 822.38. Respondents to this collection of information are those manufacturers that require PS of their products.

    In the Federal Register of June 19, 2019 (84 FR 28554), FDA published a 60-day notice requesting public comment on the proposed collection of information. No comments were received.

    FDA estimates the burden of this collection of information as follows:

    Table 1—Estimated Annual Reporting Burden 1

    Activity/21 CFR sectionNumber of respondentsNumber of responses per respondentTotal annual responsesAverage burden per responseTotal hours
    PS submission (822.9 and 822.10)251251203,000
    Changes to PS plan after approval (822.21)91940360
    Changes to PS plan for a device that is no longer marketed (822.28)616848
    Waiver (822.29)1114040
    Exemption request (822.30)1611640640
    Periodic reports (822.38)25375403,000
    1 There are no capital costs or operating and maintenance costs associated with this collection of information.

    Explanation of Reporting Burden Estimate: The burden captured in table 1 is based on the data from FDA's internal tracking system. Sections 822.26, 822.27, and 822.34 do not constitute information collection subject to review under the PRA because it entails no burden other than that necessary to identify the respondent, the date, the respondent's address, and the nature of the instrument (see 5 CFR 1320.3(h)(1)).

    Table 2—Estimated Annual Recordkeeping Burden 1

    Activity/21 CFR sectionNumber of recordkeepersNumber of records per recordkeeperTotal annual recordsAverage burden per recordkeepingTotal hours
    Manufacturer records (822.31)2512520500
    Investigator records (822.32)751755375
    1 There are no capital costs or operating and maintenance costs associated with this collection of information.

    Explanation of Recordkeeping Burden Estimate: FDA expects that at least some of the manufacturers will be able to satisfy the PS requirement using information or data they already have. For purposes of calculating burden, however, FDA has assumed that each PS order can only be satisfied by a 3-year clinically based surveillance plan, using three investigators. These estimates are based on FDA's knowledge and experience with PS.

    Our estimated burden for the information collection reflects a decrease of 29,982 hours. We attribute this adjustment to a decrease in the number of submissions we received over the last few years.

    Start Signature

    Dated: October 10, 2019.

    Lowell J. Schiller,

    Principal Associate Commissioner for Policy.

    End Signature End Supplemental Information

    [FR Doc. 2019-23205 Filed 10-23-19; 8:45 am]

    BILLING CODE 4164-01-P

Document Information

Health and Human Services Department
Food and Drug Administration
Document Number:
Fax written comments on the collection of information by November 25, 2019.
57029-57030 (2 pages)
Docket Numbers:
Docket No. FDA-2013-N-0557
PDF File: